AME Stock Analysis: Ametek | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 54.495m USD | 12M Return: 33.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 235M
EPS Trend: 99.4%
Qual. Beats: 16
Rev. Trend: 97.0%
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
AMETEK, Inc. is a U.S.-based manufacturer of electronic instruments and electromechanical devices, operating through two segments: Electronic Instruments Group (EIG) and Electromechanical Group (EMG). The company serves a broad range of end markets, including process, aerospace, power, industrial, oil and gas, petrochemical, pharmaceutical, semiconductor, automation, food and beverage, medical, test and measurement, and aerospace and defense. Its product portfolio spans precision instruments, power quality and electromagnetic compatibility equipment, sensors, motors, thermal management systems, specialty metals, electrical connectors, and precision motion control components, among others.
The company also operates a network of aviation maintenance, repair, and overhaul (MRO) facilities and supplies engineered medical components and devices, including single-use surgical instruments and drug delivery systems. Founded in 1930 and headquartered in Berwyn, Pennsylvania, AMETEK is classified within the GICS Electrical Components & Equipment sub-industry under the broader Industrials sector, reflecting its diversified industrial business model that spans thousands of niche product applications across multiple industries.
- Aerospace defense demand lifts EIG segment revenue
- Medical components expand on aging demographics and surgical trends
- Serial acquisitions drive margin expansion and revenue growth
| Net Income: 1.53b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -1.08 > 1.0 |
| NWC/Revenue: 5.02% < 20% (prev 11.51%; Δ -6.49% < -1%) |
| CFO/TA 0.11 > 3% & CFO 1.84b > Net Income 1.53b |
| Net Debt (1.76b) to EBITDA (2.36b): 0.74 < 3 |
| Current Ratio: 1.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (229.8m) vs 12m ago -0.74% < -2% |
| Gross Margin: 36.56% > 18% (prev 36.18%; Δ 0.38% > 0.5%) |
| Asset Turnover: 48.72% > 50% (prev 46.63%; Δ 2.09% > 0%) |
| Interest Coverage Ratio: 23.33 > 6 (EBIT TTM 1.94b / Interest Expense TTM 83.2m) |
| A: 0.02 (Total Current Assets 3.14b - Total Current Liabilities 2.76b) / Total Assets 16.3b |
| B: 0.77 (Retained Earnings 12.6b / Total Assets 16.3b) |
| C: 0.12 (EBIT TTM 1.94b / Avg Total Assets 15.6b) |
| D: 2.03 (Book Value of Equity 10.9b / Total Liabilities 5.39b) |
| Altman-Z'' = 5.63 = AAA |
| DSRI: 1.06 (Receivables 1.15b/996.5m, Revenue 7.60b/6.94b) |
| GMI: 0.99 (GM 36.18% / 36.56%) |
| AQI: 1.00 (AQ_t 0.74 / AQ_t-1 0.74) |
| SGI: 1.10 (Revenue 7.60b / 6.94b) |
| TATA: -0.02 (NI 1.53b - CFO 1.84b) / TA 16.3b) |
| Beneish M = -2.92 (Cap -4..+1) = A |
As of July 23, 2026, the stock is trading at USD 237.09 with a total of 855,022 shares traded. Over the past week, the price has changed by +1.53%, over one month by -1.85%, over three months by +3.03% and over the past year by +33.14%.
Current recommended Stop Loss: 224.70 (which is 5.2% or 2.2 ATR below the current price).
Ametek has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy AME.
- StrongBuy: 12
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 263.4 | 11.1% |
P/E Trailing = 35.5928
P/E Forward = 30.7692
P/S = 7.1727
P/B = 4.9372
P/EG = 3.0462
Revenue TTM = 7.60b USD
EBIT TTM = 1.94b USD
EBITDA TTM = 2.36b USD
Long Term Debt = 1.06b USD (from longTermDebt, last quarter)
Short Term Debt = 1.11b USD (from shortTermDebt, last quarter)
Debt = 2.24b USD (from shortLongTermDebtTotal, last quarter) + Leases 61.1m
Net Debt = 1.76b USD (calculated: Debt 2.24b - CCE 481.2m)
Enterprise Value = 56.3b USD (54.5b + Debt 2.24b - CCE 481.2m)
Interest Coverage Ratio = 23.33 (Ebit TTM 1.94b / Interest Expense TTM 83.2m)
EV/FCF = 33.03x (Enterprise Value 56.3b / FCF TTM 1.70b)
FCF Yield = 3.03% (FCF TTM 1.70b / Enterprise Value 56.3b)
FCF Margin = 22.42% (FCF TTM 1.70b / Revenue TTM 7.60b)
Net Margin = 20.11% (Net Income TTM 1.53b / Revenue TTM 7.60b)
Gross Margin = 36.56% ((Revenue TTM 7.60b - Cost of Revenue TTM 4.82b) / Revenue TTM)
Gross Margin QoQ = 37.21% (prev 36.93%)
Tobins Q-Ratio = 3.45 (Enterprise Value 56.3b / Total Assets 16.3b)
Interest Expense / Debt = 3.72% (Interest Expense 83.2m / Debt 2.24b)
Taxrate = 17.73% (329.4m / 1.86b)
NOPAT = 1.60b (EBIT 1.94b * (1 - 17.73%))
Current Ratio = 1.14 (Total Current Assets 3.14b / Total Current Liabilities 2.76b)
Debt / Equity = 0.21 (Debt 2.24b / totalStockholderEquity, last quarter 10.9b)
Debt / EBITDA = 0.74 (Net Debt 1.76b / EBITDA 2.36b)
Debt / FCF = 1.03 (Net Debt 1.76b / FCF TTM 1.70b)
Total Stockholder Equity = 10.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 9.80% (Net Income 1.53b / Total Assets 16.3b)
RoE = 14.39% (Net Income TTM 1.53b / Total Stockholder Equity 10.6b)
RoCE = 16.61% (EBIT 1.94b / Capital Employed (Equity 10.6b + L.T.Debt 1.06b))
RoIC = 11.17% (NOPAT 1.60b / Invested Capital 14.3b)
WACC = 9.08% (E(54.5b)/V(56.7b) * Re(9.33%) + D(2.24b)/V(56.7b) * Rd(3.72%) * (1-Tc(0.18)))
Discount Rate = 9.33% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -79.42 | Cagr: -0.38%
[DCF] Terminal Value 72.82% ; FCFF base≈1.71b ; Y1≈1.71b ; Y5≈1.79b
[DCF] Fair Price = 100.4 (EV 24.8b - Net Debt 1.76b = Equity 23.0b / Shares 229.2m; r=9.08% [WACC]; 5y FCF grow -0.62% → 2.50% )
EPS Correlation: 99.37 | EPS CAGR: 8.31% | SUE: 1.89 | # QB: 16
Revenue Correlation: 97.00 | Revenue CAGR: 5.52% | SUE: 0.27 | # QB: 0
EPS current Quarter (2026-06-30): EPS=1.99 | Chg30d=+0.10% | Revisions=-25% | Analysts=18
EPS next Quarter (2026-09-30): EPS=2.05 | Chg30d=+0.28% | Revisions=-25% | Analysts=17
EPS current Year (2026-12-31): EPS=8.15 | Chg30d=+0.15% | Revisions=-40% | GrowthEPS=+9.7% | GrowthRev=+8.3%
EPS next Year (2027-12-31): EPS=8.81 | Chg30d=-0.03% | Revisions=-25% | GrowthEPS=+8.0% | GrowthRev=+5.9%
[Analyst] Revisions Ratio: -62% (up=0, down=5)